Scientists at URMC are helping patients through research that is transforming neurosurgery. Our program is one of the nation’s leaders in this realm.
Clinical trials can provide patients with the opportunity to receive the most cutting edge care available. In many cases, a clinical trial is the only way to receive a new treatment or procedure before it is approved for public use.
The Department of Neurosurgery at URMC is the area’s leader in neurosurgery clinical trials. Through this work, we are able provide our patients with the widest range of treatment options.
Clinical trials also give patients an opportunity to help others, by helping to advance our knowledge of the best treatments for neurological disease.
Of course, it is always the patient’s option to participate in a clinical trial.
Currently, the Department of Neurosurgery at URMC is involved in clinical trials in the following areas:
The Neuromedicine Pain Management Program is actively involved in research and clinical trials to improve treatments for people with neuropathic pain. Our research helps to ensure that your patients will have the most up-to-date therapies available to them.
Our Neurosurgery Research Centers focus on innovative research that will further our understanding of neurological disease while helping to develop new treatments.
The Center for Neurodegenerative and Vascular Brain Disorders focuses on Alzheimer’s Disease and other neurodegenerative disorders such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease and Huntington’s disease. In addition to developing new therapies for these diseases, the center is also exploring novel concepts that will deepen our understanding of how these diseases work.
The Center for Translational Neuromedicine uses cell and gene therapy to develop new approaches for treating neurological disease. The center’s work emphasizes the use of a patient’s own stem and progenitor cells for structural repair. Stem cell transplant and isolation strategies are also being explored. This work holds promise for patients who suffer from diseases caused by dysfunction or loss of a single cell type, such as dysmyelinating disease.